Healthcare -
Biotechnology - NASDAQ - US
$ 0.06
-15.5 %
$ 1.01 M
Market Cap
-0.01
P/E
1. INTRINSIC VALUE
Balance Sheet
NRx Pharmaceuticals, Inc.
| Current Assets | 3.3 M |
| Cash & Short-Term Investments | 1.44 M |
| Receivables | 0 |
| Other Current Assets | 1.86 M |
| Non-Current Assets | 349 K |
| Long-Term Investments | 0 |
| PP&E | 0 |
| Other Non-Current Assets | 349 K |
| Current Liabilities | 21.9 M |
| Accounts Payable | 4.13 M |
| Short-Term Debt | 1.57 M |
| Other Current Liabilities | 16.2 M |
| Non-Current Liabilities | 5.01 M |
| Long-Term Debt | 5.01 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
NRx Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 19.7 M |
| Operating Income | -18.5 M |
| Other Expenses | 6.62 M |
| Net Income | -25.1 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
NRx Pharmaceuticals, Inc.
| Net Income | -25.1 M |
| Depreciation & Amortization | 5 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 486 K |
| Change in Working Capital | 5.29 M |
| Others | 19.2 M |
| Free Cash Flow | -10.6 M |
Wall Street Analysts Price Targets
NRx Pharmaceuticals, Inc.
NRXPW has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
NRXPW does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
NRx Pharmaceuticals, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
8. Profile
Summary
NRx Pharmaceuticals, Inc. NRXPW
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 1.01 M
Dividend Yield
0.00%
Description
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Contact
1201 Orange Street, Wilmington, DE, 19801
https://www.nrxpharma.com
IPO
Date
Dec. 1, 2017
Employees
None
Officers
Suzanne Messere
Investor Relations
Mr. Matthew Patrick Duffy
Chief Business Officer & Co-Chief Executive Officer of Hope Therapeutics
Dr. Jonathan C. Javitt M.D., M.P.H.
Co-Founder, Chief Scientist Officer, Chairman & Interim Chief Executive Officer
Mr. Michael S. Abrams
Chief Financial Officer
Dr. Philip T. Lavin Ph.D.
Chief Methodologist
Mr. Richard Clavano Narido
Treasurer
Dr. Riccardo Panicucci Ph.D.
Chief Manufacturing & Technology Officer